← All trials
NCT05208125
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2022
- Primary completion
- Mar 30, 2022
- Completion date
- Mar 31, 2023
- First posted
- Jan 26, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- IrsiCaixaLead sponsor
- University of Texas at HoustonCollaborator
- Badalona Hospital Germans Trias i PujolCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.